2. UroToday Home
  3. Video Lectures

mCRPC Treatment Videos

MEVPRO-1 and MEVPRO-2 Trials of EZH2 Inhibitor Mevrometostat in mCRPC - Neeraj Agarwal
Radioligand Therapy and Patient Selection Criteria for Lu-PSMA-617 - Phillip Koo
ProTACT Trial Investigates Next-Generation PSMA-Targeted Alpha Therapy for mCRPC - Aaron Hansen
Phase I PAnTHA Study Evaluates PSMA-Targeted Actinium-225 in mCRPC Patients - Fred Saad
CIPHER Trial Investigates Carboplatin in mCRPC Patients with HRR Mutations - Atul Batra
PEACE-3 Trial Evaluates Radium-223 Plus Enzalutamide in Bone-Metastatic mCRPC - Enrique Gallardo Diaz
BRCAAway Trial Investigates Combination Versus Sequencing of ARPI and PARP Inhibitor in mCRPC - Maha Hussain
EZH2 Inhibition Combined with ARPI Evaluated in Patients with Castration-Resistant Prostate Cancer - Nobuaki Matsubara
Real‑World Use of Radium‑223 in Veterans with Metastatic CRPC: A National Analysis - Martin Schoen
Real-World Analysis of Lutetium-177 in mCRPC by Taxane Treatment Sequence - Micah Ostrowski
ECLIPSE Trial Explores Dosimetry for PSMA-Targeted Therapy in mCRPC - Frankis Almaguel & Jason Hafron
OMAHA-003 Trial Explores CYP11A1 Inhibition in Metastatic Castration-Resistant Prostate Cancer - Evan Yu
A REtrospective Study to Describe the Real-World Treatment Landscape in Patients with Metastatic Castration-Resistant PROstate Cancer: REMPRO - Beyond the Abstract
The PLUDO Study: Comparing First-Line Lutetium vs Docetaxel in Chemo-Naive Metastatic Prostate Cancer - Kim Chi
Biomarker Data from Phase II PT-112 Trial in Heavily Pretreated mCRPC - Alan Bryce
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation - Beyond the Abstract
Radioligand Therapy Induced DNA Damage Response Kinetics and Biomarker Strategies - Katharina Lückerath & Ken Herrmann
Phase 1 Dosing Strategy and Translational Findings for Investigational Therapy Pasritamig - Karen Autio
Investigational All-in-One CAR T-Cell Platform for Prostate Cancer - Nour Shobaki
Investigational Therapies Target STEAP1 and DLL3 in Advanced Prostate Cancer - Rahul Aggarwal
Investigational RIPTAC™ Therapy (HLD-0915) in Phase I mCRPC Study – Andrew Hahn
Phase 1B Trial Combines Xaluritamig with Hormone Therapy for Metastatic Prostate Cancer - Nicholas Zorko
Targeting NSD2 to Reverse Treatment Resistance in Advanced Prostate Cancer - Jia Li
Targeting SPP1+ Macrophages and the Adenosine Pathway to Boost Prostate Cancer Immunotherapy - Lawrence Fong
ARTISAN Trial: Evaluating Lead-212 PSMA Therapy for Advanced Prostate Cancer - Oliver Sartor
International Analysis of Anti-PD-1/PD-L1 Efficacy and Biomarker Selection in Mismatch Repair-Deficient mCRPC - Niven Mehra
PARP Inhibitors in Prostate Cancer: A Decade of Development and the Combination vs Monotherapy Debate for HRR-Mutated Disease - Neeraj Agarwal
Implementing Lutetium-PSMA — From Trial Design to Operations - Oliver Sartor
Safety and Dosing of Lutetium-PSMA in the Pre-Chemotherapy PSMAfore Trial - Oliver Sartor
Real-World Analysis of Genetic Testing Rates and Barriers in Metastatic Prostate Cancer - Pedro Barata
Integrating PSMA PET Imaging: From Interpretation to Systemic Therapy Selection in Castration-Resistant Prostate Cancer - Oliver Sartor
Results from the Phase 3 PSMAfore Trial in Metastatic Castration-Resistant Prostate Cancer - Karim Fizazi
Pasritamig Bispecific Antibody in Metastatic Castration-Resistant Prostate Cancer - Mark Stein
Phase 1 Trial of an Actinium-Labeled KLK2-Targeting Antibody for mCRPC - Michael Morris
Phase I Study of SYNC-T Combination Therapy for Metastatic Castration-Resistant Prostate Cancer - Jason Hafron
PSMA PET and Radionuclide Therapy in Colombia - Carlos Granados
Development of a Prognostic Model Combining Clinical and Genetic Features in mCRPC - Andrew Armstrong
Overall Survival Results from the TALAPRO-2 Trial in mCRPC Patients - Neeraj Agarwal
Discussion on the Use of Bone Modifying Agents in Metastatic Prostate Cancer - Tian Zhang and Evan Yu
Discussion on Treatment Sequencing for mCRPC After Progression on ADT, ARPI, and Docetaxel - Phillip Kuo & Oliver Sartor
Phase III PSMAfore Trial: Final Survival and Safety Data in mCRPC, Journal Club - Rashid Sayyid & Zachary Klaassen
ctDNA Biomarkers in TheraP Trial: Cabazitaxel vs Lutetium-PSMA Comparison - Alexander Wyatt
Study Examines Racial Disparities in PSMA-PET Imaging Utilization for Metastatic Prostate Cancer - Eunice Hankinson
Advances in Targeting Cell Surface Proteins in Prostate Cancer - Andrew Hahn
VIOLET Trial of Terbium-161 PSMA-I&T in mCRPC Patients, Journal Club - Rashid Sayyid & Zachary Klaassen
COMRADE Trial: Radium-223 Plus Olaparib in Bone-Predominant mCRPC - Rana McKay
Pasritamig Safety and Efficacy Data from Metastatic CRPC Phase I Study - Capucine Baldini
EVOLUTION Trial: Ipilimumab/Nivolumab Plus Lutetium-PSMA Improves mCRPC Outcomes - Shahneen Sandhu
Darolutamide in AR-Altered mCRPC: Biomarker-Selected Phase II Trial Results - Michael Ong
Consensus Recommendations for ARPI Sequencing and Radioligand Therapy in mCRPC - Michael Morris
Xaluritamig vs. Standard Care: A Phase 3 Trial for ARPI/Taxane-Refractory mCRPC - William Kevin Kelly
Radium-223 + Enzalutamide in mCRPC: Revisiting PEACE-3 Trial Data - Kristine Peregrino Lacuna
Differential Treatment Responses Across HRR Gene Alterations in Prostate Cancer - Stefanie Zschäbitz
Dissecting Tumor Mutational Burden and Microsatellite Instability in mCRPC: Differential Responses to Immune Checkpoint Inhibitors - Nicolas Sayegh
Personalizing Lutetium-177 Dosing: The FLEX-MRT Trial Approach - Adrien Holzgreve
LIG1 Deficiency Sensitizes Prostate Cancer to PARP Inhibitors - Francesca Lorenzin & Giulia Fracassi
Circulating Tumor Cell Phenotypes and Genomic Mutations Stratify mCRPC Risk - Marina Sharifi
SUVmean on PSMA PET Predicts Lutetium-PSMA Therapy Success in mCRPC - Koichiro Kimura
Pluvicto™ Expands to Pre-Chemotherapy Space for PSMA-Positive Prostate Cancer - Steven Finkelstein
DLL3-Targeted Theranostics for Neuroendocrine Prostate Cancer - Salomon Tendler
Uncovering Blood Mutation Risks in Advanced Prostate Cancer Therapies - Asli Munzur
ENZA-p Trial: PSMA PET Guides Treatment Choice for Metastatic Prostate Cancer - Louise Emmett
Tazemetostat + Talazoparib for Metastatic Castration-Resistant Prostate Cancer - Atish Choudhury
Talazoparib-Enzalutamide Combintation and Quality of Life in mCRPC Patients - Nobuaki Matsubara
One-Button PSMA PET Quantification Predicts Survival in Metastatic Prostate Cancer - Louise Emmett
Lutetium-177 Outperforms Cabazitaxel in mCRPC: Real-World Flatiron Database Analysis - Zeynep Irem Ozay
PEACE-3 Trial: Enzalutamide Plus Radium-223 Improves Survival in mCRPC, Journal Club - Rashid Sayyid & Zachary Klaassen
Terbium-161 vs Lutetium-177: Comparing Next-Gen Radioligands for Prostate Cancer - Michael Hofman
EZH2 Inhibition in Prostate Cancer: MEVPRO-1 Phase III Trial Update - Neeraj Agarwal
Racial Disparities in mCRPC Treatment: Equal Outcomes with Equal Access to Care - Stephen Freedland
B7-H3 Targeting ADC in Castrate-Resistant Prostate Cancer Trial - Andrew Parsonson
PSMA PET Scans Predict Enzalutamide Efficacy in Metastatic Prostate Cancer - Louise Emmett
Genomic and Clinical Profiles of Rapidly Progressing mCRPC Patients - Maha Hussain
Phase I Trial Combines ONC-392 with Lutetium-177 for Prostate Cancer - David Wise
TRITON3 Subgroup Analysis: Rucaparib Benefits BRCA+ Patients with Liver Mets - David Morris
Combining Alpha and Beta Emitters in PSMA-Targeted Prostate Cancer Therapy - Scott Tagawa
Lutetium-177 PSMA Radioligand Therapy Advances to Earlier mCRPC Setting - Daniel Petrylak & Steven Finkelstein
PRECISION Data Platform Reveals mCRPC Treatment Outcomes in Urology Practices - Neal Shore
Health-Related Quality Outcomes for Pre-Chemotherapy mCRPC Treatment - Neal Shore
BMS-986365: Targeting AR Degradation and Antagonism in Metastatic Prostate Cancer - Manish Patel
First Patient Experience with Pre-Chemotherapy Pluvicto™ for mCRPC Treatment - James Wasielewski
First Patient Treated with Pluvicto™ in Pre-Chemotherapy Setting Following FDA Approval - Steven Finkelstein
Prognostic Value of ctDNA Fraction in Metastatic Castration-Resistant Prostate Cancer - Alessio Crippa
FDA Approval of 177Lu-PSMA-617 for Taxane-Naive mCRPC - Oliver Sartor
PARASEC Study Reveals Real-World Treatment Patterns After Darolutamide in ARAMIS Trial - Javier Puente
Cognitive Effects of Abiraterone vs Enzalutamide in Metastatic Castration-Resistant Prostate Cancer - Alicia Morgans
PREDICT Trial Investigates Biomarker-Guided Treatment for Advanced Prostate Cancer - Rana McKay
Real-World Treatment Delays Between Lutetium-177 and Cabazitaxel in Advanced Prostate Cancer - Yeonjung Jo & Umang Swami
Bone-Protective Agents and Survival Benefits in PEACE-3 Trial Subgroup Analysis - Fred Saad
TRITON3 Final Overall Survival Results for Rucaparib in BRCA-Mutated Prostate Cancer - Alan Bryce
Talazoparib and Enzalutamide in Unselected mCRPC Patients - Neeraj Agarwal
Revisiting HER2 as a Therapeutic Target in Prostate Cancer - Nicole Mavingire
Real-World Data on Treatment Patterns After PSMA-Targeted Therapy in mCRPC - Oliver Sartor
Targeting Lineage Plasticity in Prostate Cancer with EZH2 Inhibitor Mevrometostat - Michael Schweizer
Systematic Review of Real-World Outcomes of Radium-223 in mCRPC Treatment - Rana McKay
Phase II ENZA-p Trial Explores Effect of Lutetium PSMA With Enzalutamide - Louise Emmett
Cardiovascular Management in Advanced Prostate Cancer - Zeynep Irem Ozay
Underutilization of Genomic Testing in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata
Lutetium PSMA Therapy in mCRPC: Real-World Evidence from PRECISION Data Platform - Oliver Sartor
177-Lutetium-PSMA vs Cabazitaxel: A Real-World mCRPC Study - Mike Wenzel
ACCEL Trial Tests Actinium-225-PSMA-62 in Prostate Cancer - Ramy Saleh
Real-World Trends in Bone Health Agent Use for Metastatic Prostate Cancer - Umang Swami
REDUSE Trial: Comparing Denosumab Dosing Intervals in mCRPC - Arnoud Templeton
Talazoparib Improves Survival in HRR-Mutated mCRPC Patients in TALAPRO-2 Trial - Karim Fizazi
ASCL1 and FOXA2 in Neuroendocrine Prostate Cancer - Shaghayegh Nouruzi
Opevesostat Trial in mCRPC: Targeting Androgen Biosynthesis Upstream for Improved Outcomes - Christian Gratzke
ProstACT GLOBAL Trial: Combining PSMA-Targeted Therapy with ARPIs and Docetaxel - Oliver Sartor
Combining EZH2 and AR Targeting in Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal
AR Enhancer Amplification and SSTR1 Downregulation in mCRPC - Xiaolin Zhu
Effectiveness of PSMA-Lutetium for Prostate Cancer Liver Metastases - Daniel Childs
Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis - Ken Herrmann
Coagulation Factor X Promotes Resistance to Androgen-Deprivation Therapy in Prostate Cancer - Bianca Calì
RaLu Trial: Sequence of Radium Then Lutetium in mCRPC Management - Kambiz Rahbar
ctDNA Assay Detects AR Enhancer Alterations Linked to Poor Survival - Russell Pachynski, Aadel Chaudhuri & Christopher Maher
Optimal Treatment Sequencing in Metastatic Prostate Cancer "Discussion"
Importance of Bone Protection in Prostate Cancer Treatment "Presentation" - Noel Clarke
Tailoring PARP Inhibitor Therapy for mCRPC Based on Genetic Alterations "Discussion"
Best Use of PARP Inhibitors in mCRPC "Presentation" - Joaquin Mateo
PARP Inhibition Dissected – in Which DNA Repair Gene Alterations Works Which PARP Inhibitor? "Presentation" - Johann De Bono
How to Manage Side Effects of PARPi? "Presentation" - Elena Castro
Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment - Louise Emmett
Elevated CBP/p300 Expression Linked to Poor Outcomes in Advanced Prostate Cancer - Ayesha Shafi
Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl
Radium-223 Plus Enzalutamide Improves Survival in mCRPC: PEACE-3 Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen
Epigenetic Profiling Identifies Biomarkers Predicting Resistance to AR-Targeted Therapy in mCRPC - Wilbert Zwart
ARROW Study Reveals Iodine-131 PSMA Efficacy in Advanced Cancer - Evan Yu
AR Pathway Inhibitors vs Taxanes in mCRPC ProBio Trial - Bram De Laere
First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract
INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra
STEAP1-Targeted T-Cell Engager Demonstrates Efficacy in mCRPC Patients - William Kevin Kelly
Emerging DLL3-Targeted Therapies Demonstrate Efficacy in Neuroendocrine Prostate Cancer - Himisha Beltran
Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
First-in-Class AR Degrader Shows Promise in Castration-Resistant Prostate Cancer - Dana Rathkopf
TALAPRO-2 Analysis: Talazoparib Enzalutamide Combo in Pretreated mCRPC - Neeraj Agarwal
CONTACT-02 Trial Results: Cabozantinib Plus Atezolizumab for mCRPC - Neeraj Agarwal
PEACE-3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad
RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca
PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC - Bertrand Tombal
T-Cell Engagers in Prostate Cancer Treatment - Neeraj Agarwal
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment - Oliver Sartor
STORM Trial Examines Elective Nodal Radiotherapy in Treating Prostate Cancer Recurrence - Piet Ost
Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer - Daniel Petrylak
Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan
PSMA PET in Prostate Cancer: Balancing Sensitivity and Clinical Relevance - Ravi Madan
Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo
2024 NCCN Guidelines: Managing Bone Health in Prostate Cancer Patients - Rashid Sayyid & Zachary Klaassen
2024 NCCN Guidelines: Preventing Skeletal Events in Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner
2024 NCCN Guidelines Update: Metastatic Castration-Resistant Prostate Cancer Treatment - Rashid Sayyid & Zachary Klaassen
PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi
Meta-Analysis Evaluates Cardiovascular Risks of AR Inhibitors in Prostate Cancer - Omar El-Taji & Ashwin Sachdeva
SECuRE Trial: Copper-67 SAR-bisPSMA Therapy for Prostate Cancer - Geoffrey Johnson
Genomic Alterations and Lutetium PSMA Response in Prostate Cancer - Alexandra Sokolova
CYCLONE 2 Trial Results: Abemaciclib in Metastatic Castration-Resistant Prostate Cancer - Matthew Smith
PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results - Tanya Dorff
Targeting EZH2 in Prostate Cancer: The Role of Mevrometostat in Preventing Neuroendocrine Differentiation - Michael Schweizer
Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh
ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC - Edmond Kwan
Dose-Escalation of Lutetium PSMA: Final Results from a Phase I/II Trial - Scott Tagawa
Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski
OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan
ARV-766: Efficacy and Safety of a Second-Generation AR Degrader in Prostate Cancer - Daniel Petrylak
CHAARTED 2 Study Shows PFS Benefit with Cabazitaxel in Metastatic Prostate Cancer in Phase 2 - Christos Kyriakopoulos
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi
hK2-Targeted Radioligand Shows Promise in Treating Advanced Prostate Cancer: Phase I Findings - Michael Morris
Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Fred Saad
Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo
Reprogramming Tumor-Associated Macrophages with Glutamine Antagonist JHU083 in Prostate Cancer - Jelani Zarif
PARP Inhibitor + AR Signaling Inhibitor Combos Improve mCRPC Outcomes in Meta-Analysis - Rashid Sayyid
Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce
COMBAT Trial Yields Promising Results for Bipolar Androgen Therapy Plus Nivolumab in Metastatic Castration-Resistant Prostate Cancer - Mark Markowski & Emmanuel Antonarakis
BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer - Maha Hussain
CONTACT-02 Phase III Trial Findings on Cabozantinib-Atezolizumab Combination in mCRPC - Neeraj Agarwal
BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George
ProBio Trial Demonstrates Improved Outcomes Using Biomarker-Guided Therapy Selection for Metastatic Prostate Cancer - Henrik Grönberg
Novel Biomarker Analysis Reveals SPOP Gene Mutation Unlocks Sensitivity to PARP Inhibitor Treatment in Metastatic Castration-Resistant Prostate Cancer - Emmanuel Antonarakis & Jacob Orme
Dual Action Hormone Therapy Targeting Two Parts of Androgen Receptor Shows Tolerability and Early Efficacy for EPI-7386 (masofaniten) - Andrew Laccetti
STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly
Medicare Data Compares Enzalutamide and Abiraterone Outcomes in mCRPC Patients - Dan George
Sequencing Therapies in Advanced Prostate Cancer Requires Balancing Many Factors - Rana McKay
The PSMAfore Trial and its Role in Shaping Future Prostate Cancer Treatments - Oliver Sartor
AKT Inhibitors – Targeting PI3K/AKT/MTOR Signaling Axis - Cora Sternberg
Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming
Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer - Rana McKay
Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi
PARP Inhibitors: Targeting DNA Repair Pathways - Neal Shore
The Biological Basis of Metastatic Prostate Cancer – The Unmet Medical Need for New Targets and Novel Treatment Pathways - Dan George
The Critical Intersection of Androgen Receptor Pathways and Cell Cycle Regulation in Prostate Cancer Therapy - Rana McKay
2023 Key Learnings in mCRPC Treatments – Alicia Morgans
Treatment Decision Making in mCRPC: The Urologist and Patient “What the Patient Needs to Know” About His Disease and Treatment Options? - Brenda Martone
Multidisciplinary Approach in the Treatment of Metastatic Prostate Cancer - Robert Dreicer
Exploring the Safety and Efficacy of EPI-7386 in Combination with Enzalutamide in mCRPC - Ronald Tutrone
A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy - Beyond the Abstract
The ECLIPSE Trial: Investigating Lutetium-177 in the Pre-Chemotherapy Space in Advanced Prostate Cancer - Daniel Saltzstein
Impact of Previous Local Treatment on First-line Androgen Receptor Axis Targeted Therapy Response in mCRPC: A Secondary Analysis of the COU-AA-302 Trial - Soumyajit Roy
Exploring the Clinical Trial Landscape for Metastatic Castration-Resistant Prostate Cancer: Insights on Genetic Testing, Radiopharmaceuticals, and Promising Trials - Elena Castro
Breaking Down Barriers: Feasibility of Internet-based Genetic Testing for Men with Metastatic Prostate Cancer, The GENTleMEN Study -Heather Cheng
PSMA-Targeted Radioligand Therapy and Liquid Biopsy Characterizing PSMA Expression in Men with Metastatic Castration-Resistant Prostate Cancer - Andrew Armstrong
Elucidating Mechanisms of Resistance to ADT/PI3K-AKT Blockade in PTEN-Deficient mCRPC - Akash Patnaik
The ECLIPSE Phase III Trial of Lutetium PSMA-I&T Shows Promise in Advanced Prostate Cancer Treatment - Emmanuel Antonarakis
Exploring the Latest Advances in Advanced Prostate Cancer Treatment - Oliver Sartor
BXCL701 Combined with Pembrolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer of Small Cell Neuroendocrine Phenotype - Rahul Aggarwal
Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad
Clinically Relevant Biomarkers in Castration-Resistant Prostate Cancer - Noel Clarke
Combination of Niraparib and Abiraterone Acetate Plus Prednisone Radiographic PFS as a First-Line Therapy in Patients with HRR Gene-Mutated mCRPC, MAGNITUDE - Cora Sternberg
Heterogeneity in Multifocal Prostate Cancer - Simpa Salami
A Urine-Based Multiplexed Assay for the Early Detection of Aggressive Prostate Cancer – Simpa Salami
Rucaparib Monotherapy Improves Radiographic Progression-Free Survival in Patients With Metastatic Castration-Resistant Prostate Cancer: TRITON3 Trial - Alan Bryce
Radiographic Progression-Free Survival Correlation with Time-to-Event Endpoints in the VISION Trial - Michael Morris
Exploring the Molecular Mechanisms of Tumor Progression in Metastatic Prostate Cancer among Men of African Ancestry (MET-PAAM) - Clayton Yates
Bipolar Androgen Therapy in the Management of Prostate Cancer - Samuel Denmeade
Developing a Blood-Based Biomarker Platform to Predict Treatment Outcomes in Prostate Cancer Patients - Martin Sjöström
Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis
Exploring the Landscape of mCRPC: PARP Inhibitors, PSMA Radioligand Therapy, and More - Alicia Morgans
Exploring the SPLASH Trial: PSMA I&T Lutetium-177 in Pre-Chemo Metastatic CRPC - Oliver Sartor
A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore
ODM-208: A New Hope for Treatment-Resistant Prostate Cancer - Karim Fizazi
A Urologist's Perspective on the PROpel Trial, Olaparib and Abiraterone versus Abiraterone Alone, in the First-Line Metastatic Castration-Resistant Prostate Cancer Setting - Neal Shore
Optimal Treatment for Poor Prognosis Metastatic Castration-Resistant Prostate Cancer, Cabazitaxel vs Abi/Enza, Journal Club – Christopher Wallis & Zachary Klaassen
Debate: PARP Inhibitors for All mCRPC Patients APCCC 2022 Presentation - Noel Clarke
Risk-Adapted Treatment Monitoring in mCRPC APCCC 2022 Presentation - Anwar Padhani
Is There Still a Role for Radium-223? APCCC 2022 Presentation - Neal Shore
How To Read a Genomic Testing Report APCCC 2022 Presentation - Kim Chi
Optimal Treatment Sequencing in mCRPC APCCC 2022 Presentation - Maha Hussain
Treating Metastatic Castration-Resistant Prostate Cancer Session Discussion APCCC 2022 Presentation - Silke Gillessen
Debate: PARP Inhibitors Only in Selected mCRPC Patients APCCC 2022 Presentation - Johann de Bono
Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo
Treatment with Radium-223 and Effects on Bone Health in Patients with mCRPC - Fred Saad
The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo
Symptomatic and Health Related Quality of Life Benefits With Olaparib in Men With mCRPC Carrying Mutations in the Homologous Recombination Repair Genes, Journal Club - Christopher Wallis & Zachary Klaassen
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
Significant Improvement With Continuous Enzalutamide in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer – Axel Merseburger
The Risk of Prostate Cancer in Men with Inherited Germline TP53 Variants - Kara Maxwell
First Results of MAGNITUDE – Niraparib with Abiraterone Acetate and Prednisone a First-Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Kim Chi
Risk Stratification in Metastatic Prostate Cancer: The Genomic Approach - Leanne Schimke
Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor
CheckMate 9KD Trial CohortA2 Evaluating Nivolumab + Rucaparib for Chemotherapy-Naïve mCRPC - Daniel Petrylak
Decoding the Impact of CHIP on Prostate Cancer Treatment: Implications for PARP Inhibitor Eligibility - Kendal Jensen
COSMIC-021 Study: A Breakthrough in Metastatic CRPC Treatment with Cabozantinib and Atezolizumab - Neeraj Agarwal
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi
The Efficacy of Olaparib in the PROfound Study – Fred Saad
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
Assessing Concordance in DDR Gene Alterations Between Primary Prostate Cancer and Metastases or ctDNA – Bruce Montgomery
COncurrent adMinistration of Bipolar Androgen Therapy and nivolumab in men with mCRPC, The COMBAT Study - Mark Markowski
Ensuring Patients Have Access to Radium-223 as a Therapeutic Option: The DORA Trial - Michael Morris
The State of CRPC Treatment in Spain: Expert Opinions on Enzalutamide and Abiraterone - Elena Castro & Fernando Lopez-Campos
Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit
TRANSFORMER - A Study Comparing Bipolar Androgen Therapy Vs Enzalutamide in mCRPC - Emmanuel Antonarakis
Should Checkpoint Inhibitors Ever Be Used Outside of a Clinical Trial in Prostate Cancer - James Gulley
How Can We Leverage Our Understanding of the Tumor Microenvironment to Improve Systemic Therapy? - Kenneth Pienta
Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal
NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans
Improving Quality Imaging in Prostate Cancer with Gallium 68 PSMA-11 - Johannes Czernin
Discussing the Efficacy and Safety from Results of the Dose Escalation Arm of AMG 160, a Bispecific T-Cell Engager (BiTE) Immune Therapy Targeting PSMA for Metastatic Castration-Resistant Prostate Cancer - Ben Tran, Oliver Sartor, and Neal Shore
Preliminary Efficacy of AMG 160 in Metastatic Castration-Resistant Prostate Cancer, Interim Results From the Phase 1 Study - Tanya Dorff
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer - Karim Fizazi
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran
Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans
PROfound: Olaparib for Metastatic Castrate Resistant Prostate Cancer - Thomas Keane
Effect of Cabazitaxel vs Abiraterone or Enzalutamide on Patient-Reported Outcomes in mCRPC: A Pre-Planned EQ-5D-5L Analysis of the CARD Study - Neal Shore
Cabazitaxel Demonstrates Improved Overall Survival when Compared to an Alternative AR-targeted Agent (CARD) - Cora Sternberg
The Clinical Implications of The Efficacy and Safety in Older Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone or Enzalutamide In The CARD Trial - William Oh and Stephen Freedland
Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Sweeney
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer - Rahul Aggarwal
FDA Approves First PARP Inhibitor Rucaparib for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Charles Ryan
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor
Optimal Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Evan Yu
The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran
The Clinical Implications and Health-related Quality of Life Benefits: Reviewing the CARD Study Results in Men with mCRPC - Neal Shore
CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi
Results and Lessons Learned from the Consensus Conference for Developing Countries - Fernando Maluf
Immunotherapy in Metastatic Prostate Cancer - Charles Drake
Personalized Medicine in Prostate Cancer - Arpit Rao
Radiation Oncology Studies: Changing the Course of Disease for Men with Metastatic Prostate Cancer - Phuoc Tran
Bone Health Agents in Patients with Castrate-Resistant Prostate Cancer - Bertrand Tombal
The Current State of Cell-free DNA in Prostate Cancer - Alexander Wyatt
RET Signaling in Neuroendocrine Prostate Cancer - Justin Drake
Optimal Steroid Use with Abiraterone - Gerhardt (Gert) Attard
Antibody-drug Conjugates for Metastatic Urothelial Carcinoma & 177Lu-PSMA-617 for Progressive mCRPC - Scott Tagawa
Clinical Implications of the CARD Trial - Cora Sternberg
Immunotherapy and Personalized Medicine in Prostate Cancer - Akash Patnaik
New Therapeutic Targets for Metastatic Castration-Resistant Prostate Cancer - Aaron LeBeau
Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer - Bertrand Tombal
Management of Castration-Resistant Prostate Cancer - Cora Sternberg
Guiding First Line Treatment Decisions for mCRPC After ADT + Docetaxel or AR Pathway Inhibitor - Mary-Ellen Taplin
Local Treatment of the Primary Tumor (Radiotherapy) in the Metastatic Setting - Robert Bristow
Oligometastatic Prostate Cancer – Definitions and Concepts Presentation - Robert Reiter
PARP Inhibition for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presentation - Kim Chi
Treatment of Oligometastatic and Oligoprogressive CRPC Presentation - Eric Small
Oligorecurrent Prostate Cancer Presentation - Piet Ost
De-Novo Oligometastatic Disease: Consensus and Controversy on Aims, Options, and Rationale Presentation - Michael J. Morris
Immunotherapy for Metastatic Castration Resistant Prostate Cancer Presentation - Charles Drake
Clinical Trial Treatment Options for Rare GU Malignancies - Bradley McGregor
Local Treatment of the Primary Tumor (Surgery) in the Metastatic Setting Presentation - Thomas Steuber
Report and Lessons Learned From The Consensus Conference For Developing Countries Presentation - Fernando Maluf
A Prognostic Model for Overall Survival in Men with Metastatic Castration-resistant Prostate Cancer - Susan Halabi
Radium-223 in Clinical Practice - Phillip J. Koo
Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients – Oliver Sartor
DKK1 and Prostate Cancer - David Wise
Management of mCRPC using Sipuleucel-T - Evan Yu
Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal
Contemporary Sequencing in the Treatment of Prostate Cancer - Neal Shore, Alicia Morgans and Charles Ryan
The Changing Therapeutic Landscape of Prostate Cancer- Nicholas Vogelzang
Improved Survival Outcomes of African America Men with mCRPC Treated with Sipuleucel-T - Kelvin Moses
Treatment Decisions for Patients with Metastatic Castration-resistant Prostate Cancer: A Retrospective Study of Real-World Experience - Tia Higano
Racial Disparities in Prostate Cancer Treatment and Outcomes - Susan Halabi
Improving Natural Killer Cell Immunotherapy for Cancer - Martin Felices
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer - Oliver Sartor
The Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade - Wassim Abida
Targeting Glutamine Metabolism Pathways for the Treatment of Prostate Cancer - Richard Lee
Introducing TIN 117m for Convention Electron Therapy of mCRPC - Suresh Srivastava
PROPHECY Trial: Circulating Tumor Cell as a Biomarker in mCRPC - Andrew Armstrong
The Process of Metastasis in Prostate Cancer - Kenneth Pienta
An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.
Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad
Prospective Study of Low-Dose Abiraterone with Food Versus Standard Dose Abiraterone in mCRPC - Russell Szmulewitz
Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad
UPWARD Study - Seizure Rates in Enzalutamide-Treated Men with mCRPC - Susan Slovin